Nicholasville

Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition affecting the peripheral nerves. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study aims to understand how well Imeroprubart works compared to placebo in treating CIDP. The study is sponsored by Immunovant Sciences GmbH and focuses specifically on adults meeting diagnostic criteria for typical or variant forms of CIDP. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The treatment period includes an initial 24-week phase Period 1 with Imeroprubart or placebo, followed by an extension to 52 weeks Period 2 for continued evaluation. Imeroprubart dosing is given once weekly via subcutaneous injection. Placebo is provided similarly during the first 24 weeks. During the study, participants will be monitored through clinical assessments including relapse status by Week 24, as well as measurements of disability, grip strength, muscle strength, and symptom scores. Electrodiagnostic tests support diagnosis at baseline. Safety and efficacy will be closely observed during treatment, with follow-up visits scheduled to assess outcomes. The total participation duration covers at least 24 weeks for the primary outcome assessment, with ongoing monitoring as defined by the study protocol.

Researchers are studying the effects of IMVT-1402 in adults with mild to severe generalized myasthenia gravis, a condition affecting muscle strength. This Phase 3 trial aims to evaluate the efficacy, safety, and tolerability of IMVT-1402 as a treatment option compared to a placebo. The study is randomized and triple-blinded to ensure reliable results. Participants will receive one of two doses of IMVT-1402 or a placebo, all administered by subcutaneous injection once weekly. The treatment periods include an initial 12-week phase, followed by extended dosing periods of 14 weeks and 52 weeks for some groups. The study is designed to assess responses across these timeframes. During the trial, participants will be monitored through various assessments including the MG activities of daily living MG-ADL score and the Quantitative Myasthenia Gravis QMG score. The main outcome focuses on changes in MG-ADL from baseline to week 12. Safety and tolerability will also be tracked throughout the treatment and follow-up periods. The overall participation may last up to several months depending on the treatment group.